31 related articles for article (PubMed ID: 34044271)
1. Pathology of breast cancer metastasis and a view of metastasis to the brain.
Sakibuzzaman M; Mahmud S; Afroze T; Fathma S; Zakia UB; Afroz S; Zafar F; Hossain M; Barua A; Akter S; Chowdhury HI; Ahsan E; Eshan SH; Fariza TT
Int J Neurosci; 2023 May; 133(5):544-554. PubMed ID: 34044732
[TBL] [Abstract][Full Text] [Related]
2. Combining Liquid Oral Drugs with Thickener: Compatibility and Changes in Viscosity.
Bravo-José P; Sáez-LLeó C; Moreno-Guillamont E
Dysphagia; 2022 Aug; 37(4):889-899. PubMed ID: 34373976
[TBL] [Abstract][Full Text] [Related]
3. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
4. Delineating the glioblastoma stemness by genes involved in cytoskeletal rearrangements and metabolic alterations.
Kałuzińska-Kołat Ż; Kołat D; Kośla K; Płuciennik E; Bednarek AK
World J Stem Cells; 2023 May; 15(5):302-322. PubMed ID: 37342224
[TBL] [Abstract][Full Text] [Related]
5. mTOR pathway as a potential therapeutic target for cancer stem cells in canine mammary carcinoma.
Michishita M; Ochiai K; Nakahira R; Azakami D; Machida Y; Nagashima T; Nakagawa T; Ishiwata T
Front Oncol; 2023; 13():1100602. PubMed ID: 36816969
[TBL] [Abstract][Full Text] [Related]
6. Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance.
Rahim NS; Wu YS; Sim MS; Velaga A; Bonam SR; Gopinath SCB; Subramaniyan V; Choy KW; Teow SY; Fareez IM; Samudi C; Sekaran SD; Sekar M; Guad RM
Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678607
[TBL] [Abstract][Full Text] [Related]
7. Screening of GPCR drugs for repurposing in breast cancer.
Abdulkareem NM; Bhat R; Powell RT; Chikermane S; Yande S; Trinh L; Abdelnasser HY; Tabassum M; Ruiz A; Sobieski M; Nguyen ND; Park JH; Johnson CA; Kaipparettu BA; Bond RA; Johnson M; Stephan C; Trivedi MV
Front Pharmacol; 2022; 13():1049640. PubMed ID: 36561339
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities.
Huang Z; Zhang Z; Zhou C; Liu L; Huang C
MedComm (2020); 2022 Jun; 3(2):e144. PubMed ID: 35601657
[TBL] [Abstract][Full Text] [Related]
9. Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds.
Maiuthed A; Chantarawong W; Chanvorachote P
Anticancer Res; 2018 Jul; 38(7):3797-3809. PubMed ID: 29970499
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput screen identifies inhibitors of lung cancer stem cells.
She X; Gao Y; Zhao Y; Yin Y; Dong Z
Biomed Pharmacother; 2021 Aug; 140():111748. PubMed ID: 34044271
[TBL] [Abstract][Full Text] [Related]
12. A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.
Mathews LA; Keller JM; Goodwin BL; Guha R; Shinn P; Mull R; Thomas CJ; de Kluyver RL; Sayers TJ; Ferrer M
J Biomol Screen; 2012 Oct; 17(9):1231-42. PubMed ID: 22927676
[TBL] [Abstract][Full Text] [Related]
13. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.
Nishi M; Akutsu H; Kudoh A; Kimura H; Yamamoto N; Umezawa A; Lee SW; Ryo A
Oncotarget; 2014 Sep; 5(18):8665-80. PubMed ID: 25228591
[TBL] [Abstract][Full Text] [Related]
14. Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.
Yang J; Fang Z; Wu J; Yin X; Fang Y; Zhao F; Zhu S; Li Y
Tumour Biol; 2016 Oct; 37(10):13871-13883. PubMed ID: 27485114
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
